Waters Corporation announced its financial results for the first quarter of 2025 on May 6, 2025, with sales reaching $662 million, a 4% increase as reported and 7% in constant currency, exceeding expectations. Diluted GAAP earnings per share (EPS) for the quarter was $2.03, while non-GAAP EPS was $2.25, representing 2% growth despite unfavorable foreign exchange impacts.
The company reported double-digit instrument growth and strong performance in the pharmaceutical sector, driven by its innovative product portfolio. Waters' unique exposure to resilient, downstream applications and commitment to operational excellence contributed to these results.
Based on this strong start, Waters raised its full-year 2025 constant currency sales growth guidance to a range of +5.0% to +7.0%, and its non-GAAP EPS guidance to $12.75 to $13.05, reflecting approximately 8% to 10% year-over-year growth. For the second quarter of 2025, the company expects constant currency sales growth of 5.0% to 7.0% and non-GAAP EPS between $2.88 and $2.98.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.